These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 7931462)

  • 1. Cellular and signaling mechanisms of cardiac hypertrophy.
    Piano MR
    J Cardiovasc Nurs; 1994 Jul; 8(4):1-26. PubMed ID: 7931462
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Significance of left ventricular hypertrophy in cardiovascular morbidity and mortality.
    Kaplinsky E
    Cardiovasc Drugs Ther; 1994 Aug; 8 Suppl 3():549-56. PubMed ID: 7841088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alteration of growth responses in established cardiac pressure overload hypertrophy in rats with aortic banding.
    Schunkert H; Weinberg EO; Bruckschlegel G; Riegger AJ; Lorell BH
    J Clin Invest; 1995 Dec; 96(6):2768-74. PubMed ID: 8675646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiotensin II receptor antagonist TCV-116 induces regression of hypertensive left ventricular hypertrophy in vivo and inhibits the intracellular signaling pathway of stretch-mediated cardiomyocyte hypertrophy in vitro.
    Kojima M; Shiojima I; Yamazaki T; Komuro I; Zou Z; Wang Y; Mizuno T; Ueki K; Tobe K; Kadowaki T
    Circulation; 1994 May; 89(5):2204-11. PubMed ID: 8181146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural basis for pathologic left ventricular hypertrophy.
    Weber KT; Brilla CG
    Clin Cardiol; 1993 May; 16(5 Suppl 2):II10-4. PubMed ID: 8504584
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical impact of left ventricular hypertrophy and implications for regression.
    Artham SM; Lavie CJ; Milani RV; Patel DA; Verma A; Ventura HO
    Prog Cardiovasc Dis; 2009; 52(2):153-67. PubMed ID: 19732607
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduction of left ventricular hypertrophy: how beneficial?
    Messerli FH; Aristizabal D; Soria F
    Am Heart J; 1993 May; 125(5 Pt 2):1520-4. PubMed ID: 8480623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Salt sensitivity and left ventricular hypertrophy.
    Coca A; De la Sierra A
    Adv Exp Med Biol; 1997; 432():91-101. PubMed ID: 9433515
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiotensin-converting enzyme inhibition prolongs survival and modifies the transition to heart failure in rats with pressure overload hypertrophy due to ascending aortic stenosis.
    Weinberg EO; Schoen FJ; George D; Kagaya Y; Douglas PS; Litwin SE; Schunkert H; Benedict CR; Lorell BH
    Circulation; 1994 Sep; 90(3):1410-22. PubMed ID: 8087951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiotensin II requires an intact cardiac thyrotropin-releasing hormone (TRH) system to induce cardiac hypertrophy in mouse.
    Peres Diaz LS; Schuman ML; Aisicovich M; Toblli JE; Pirola CJ; Landa MS; García SI
    J Mol Cell Cardiol; 2018 Nov; 124():1-11. PubMed ID: 30267750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stage-specific differential activation of mitogen-activated protein kinases in hypertrophied and failing rat hearts.
    Hayashida W; Kihara Y; Yasaka A; Inagaki K; Iwanaga Y; Sasayama S
    J Mol Cell Cardiol; 2001 Apr; 33(4):733-44. PubMed ID: 11273726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Left ventricular hypertrophy: should it be reduced?
    Messerli FH; Soria F; Aristizabal D
    Clin Cardiol; 1993 May; 16(5 Suppl 2):II15-20. PubMed ID: 8504585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myocardial hypertrophy is not a prerequisite for changes in early gene expression in left ventricular volume overload.
    Dzimiri N; Al-Bahnasi K; Al-Halees Z
    Fundam Clin Pharmacol; 2004 Feb; 18(1):39-44. PubMed ID: 14748752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early onset of chondroitin sulfate and osteopontin expression in angiotensin II-dependent left ventricular hypertrophy.
    Rothermund L; Kreutz R; Kossmehl P; Fredersdorf S; Shakibaei M; Schulze-Tanzil G; Paul M; Grimm D
    Am J Hypertens; 2002 Jul; 15(7 Pt 1):644-52. PubMed ID: 12118914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Left-ventricular hypertrophy as a cardiac risk factor: role of the renin-angiotensin-aldosterone system].
    Erne P
    Praxis (Bern 1994); 1996 Feb; 85(8):227-33. PubMed ID: 8701189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Left ventricular hypertrophy: how to influence an important risk factor in hypertension.
    Agabiti-Rosei E; Muiesan ML
    J Hypertens Suppl; 1998 Jan; 16(1):S53-8. PubMed ID: 9534098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Involvement of the renin-angiotensin system in the development of left ventricular hypertrophy and dysfunction.
    Yamazaki T; Shiojima I; Komuro I; Nagai R; Yazaki Y
    J Hypertens Suppl; 1994 Dec; 12(10):S153-7. PubMed ID: 7769485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Substrate metabolism, hormone interaction, and angiotensin-converting enzyme inhibitors in left ventricular hypertrophy.
    Zhu YC; Zhu YZ; Spitznagel H; Gohlke P; Unger T
    Diabetes; 1996 Jan; 45 Suppl 1():S59-65. PubMed ID: 8529802
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiotensin II-induced cardiomyocyte hypertrophy and cardiac fibrosis in stroke-prone spontaneously hypertensive rats.
    Ikeda Y; Nakamura T; Takano H; Kimura H; Obata JE; Takeda S; Hata A; Shido K; Mochizuki S; Yoshida Y
    J Lab Clin Med; 2000 Apr; 135(4):353-9. PubMed ID: 10779052
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation of beta myosin heavy chain, c-myc and c-fos proto-oncogenes in thyroid hormone-induced hypertrophy of the rat myocardium.
    Green NK; Gammage MD; Franklyn JA; Heagerty AM; Sheppard MC
    Clin Sci (Lond); 1993 Jan; 84(1):61-7. PubMed ID: 8382136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.